NCT00678626View on ClinicalTrials.gov

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

April 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Breast Cancer

Interventions

DRUG

CP-751,871

Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.

DRUG

Docetaxel

Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.